MA20938A1 - Procede de preparation du besylate d'amlodipine. - Google Patents

Procede de preparation du besylate d'amlodipine.

Info

Publication number
MA20938A1
MA20938A1 MA21175A MA21175A MA20938A1 MA 20938 A1 MA20938 A1 MA 20938A1 MA 21175 A MA21175 A MA 21175A MA 21175 A MA21175 A MA 21175A MA 20938 A1 MA20938 A1 MA 20938A1
Authority
MA
Morocco
Prior art keywords
amlodipine besylate
preparing amlodipine
preparing
besylate
amlodipine
Prior art date
Application number
MA21175A
Other languages
English (en)
Inventor
Edward Davison
James Ingram Wells
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA20938(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MA20938A1 publication Critical patent/MA20938A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
MA21175A 1986-04-04 1987-04-03 Procede de preparation du besylate d'amlodipine. MA20938A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868608335A GB8608335D0 (en) 1986-04-04 1986-04-04 Pharmaceutically acceptable salts

Publications (1)

Publication Number Publication Date
MA20938A1 true MA20938A1 (fr) 1987-12-31

Family

ID=10595731

Family Applications (1)

Application Number Title Priority Date Filing Date
MA21175A MA20938A1 (fr) 1986-04-04 1987-04-03 Procede de preparation du besylate d'amlodipine.

Country Status (47)

Country Link
US (1) US4879303A (fr)
EP (1) EP0244944B1 (fr)
JP (1) JPS62240660A (fr)
KR (1) KR950006710B1 (fr)
CN (1) CN1023800C (fr)
AP (1) AP50A (fr)
AR (1) AR242562A1 (fr)
AT (1) ATE49752T1 (fr)
BE (1) BE1000130A4 (fr)
BG (1) BG60698B2 (fr)
CA (1) CA1321393C (fr)
CS (1) CS265237B2 (fr)
CY (1) CY1669A (fr)
CZ (1) CZ289095B6 (fr)
DD (1) DD265142A5 (fr)
DE (2) DE3710457A1 (fr)
DK (1) DK171708B1 (fr)
EC (1) ECSP941129A (fr)
EG (1) EG18266A (fr)
ES (2) ES2012803B3 (fr)
FI (1) FI85017C (fr)
FR (1) FR2596758B1 (fr)
GB (2) GB8608335D0 (fr)
GR (2) GR870525B (fr)
HK (1) HK76092A (fr)
HU (1) HU196962B (fr)
IE (1) IE59457B1 (fr)
IL (1) IL82101A (fr)
IN (1) IN168414B (fr)
IT (1) IT1203853B (fr)
LU (1) LU86812A1 (fr)
MA (1) MA20938A1 (fr)
MX (1) MX5847A (fr)
MY (1) MY101177A (fr)
NL (1) NL8700791A (fr)
NO (1) NO172181C (fr)
NZ (1) NZ219868A (fr)
PH (1) PH24348A (fr)
PL (1) PL149532B1 (fr)
PT (1) PT84611B (fr)
SE (1) SE463457B (fr)
SG (1) SG59692G (fr)
SK (1) SK278435B6 (fr)
SU (1) SU1498388A3 (fr)
UA (1) UA6344A1 (fr)
YU (1) YU44801B (fr)
ZA (1) ZA872439B (fr)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
JPH07501547A (ja) * 1991-11-26 1995-02-16 セプラコア，インコーポレーテッド 光学的に純粋な（−）アムロジピンを用いる，高血圧，狭心症および他の疾患を治療するための方法および組成物
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
AT399718B (de) * 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
US5389654A (en) * 1992-11-26 1995-02-14 Lek, Tovarna, Farmacevtskih In Kemicnih . . . 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate
SI9200344B (sl) * 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CA2215234C (fr) 1995-03-16 2001-12-11 Pfizer Inc. Composition renfermant de l'amlopidine ou un sel, ou de la felodipine et un inhibiteur de l'enzyme de conversion de l'angiotensine
HU221810B1 (hu) * 1997-08-12 2003-01-28 EGIS Gyógyszergyár Rt. Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
WO1999018957A1 (fr) * 1998-03-26 1999-04-22 Reddy-Cheminor, Inc. Composition pharmaceutique stable contenant du besylate d'anilodipine et de l'atenolol
PL189666B1 (pl) * 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
ES2552639T3 (es) 1998-07-10 2015-12-01 Novartis Pharma Ag Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7129265B2 (en) * 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
CA2375372C (fr) 1999-05-27 2007-01-09 George Chang Promedicaments communs d'amlodipine et d'atorvastatine
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
UA72768C2 (en) 1999-07-05 2005-04-15 Richter Gedeon Vegyeszet A method for obtaining amilodipine benzenesulphonate
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
WO2002011723A1 (fr) 2000-08-04 2002-02-14 Mason R Preston Effet synergétique de l'amlodipine et de l'atorvastatine
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
ES2254495T4 (es) 2000-12-29 2007-06-16 Pfizer Limited Hemimaleato de amlodipina.
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
GB2372036B (en) * 2000-12-29 2004-05-19 Bioorg Bv Aspartate derivative of amlodipine
WO2002053541A1 (fr) 2000-12-29 2002-07-11 Pfizer Limited Derive d'amide d'amlodipine
EP1309556B1 (fr) 2000-12-29 2004-11-24 Pfizer Limited Fumarate d'amlodipine
US6653481B2 (en) * 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
WO2002053542A1 (fr) 2000-12-29 2002-07-11 Pfizer Limited Procede de preparation de maleate d'amlodipine
EP1346214A2 (fr) 2000-12-29 2003-09-24 Pfizer Limited Standards de reference destines a la determination de la purete ou de la stabilite de maleate d'amlodipine et procedes correspondants
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
ATE356806T1 (de) * 2001-01-09 2007-04-15 Siegfried Generics Int Ag Salze von amlodipin-mesylat
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
US20030027848A1 (en) * 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
ATE454890T1 (de) 2001-07-06 2010-01-15 Lek Pharmaceuticals Verfahren zur herstellung hochreines amlodipinbenzolsulfonat
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
US6828339B2 (en) * 2001-11-21 2004-12-07 Synthon Bv Amlodipine salt forms and processes for preparing them
HU226642B1 (en) * 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
EP1499592A4 (fr) * 2002-04-13 2010-01-13 Hanlim Pharmaceutical Co Ltd Nicotinate d'amlodipine et son procede de preparation
CN101648028B (zh) 2002-05-06 2012-11-21 恩多塞特公司 维生素-定向的显象剂
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SI21233A (sl) * 2002-05-31 2003-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Kristalni hidratni obliki amlodipin benzensulfonata visoke čistote, postopki za njuno pripravo in uporaba
US6699892B2 (en) 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
KR20040011751A (ko) * 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
KR100496436B1 (ko) * 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) * 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
EA007613B1 (ru) 2002-08-29 2006-12-29 Тайсо Фармасьютикал Ко., Лтд. Бензолсульфонатная соль (2s,4s)-1-циано-4-фтор-1-[(2-гидрокси-1,1-диметил)этиламино]ацетилпирролидина
US6784297B2 (en) * 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
AU2003260984A1 (en) * 2002-09-11 2004-04-30 Hanlim Pharmaceutical Co., Ltd. S-(-)-amlodipine nicotinate and process for the preparation thereof
WO2004026834A1 (fr) * 2002-09-19 2004-04-01 Cj Corporation Sel acide organique cristallin d'amlodipine
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
EP1407773A1 (fr) * 2002-10-08 2004-04-14 Council of Scientific and Industrial Research Procede pour la preparation des sels de s(-)amlodipine
US20040072879A1 (en) * 2002-10-10 2004-04-15 Dr. Reddy's Laboratories Limited Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)
AU2002368531A1 (en) * 2002-12-30 2004-07-22 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Isolation of dihydropyridine derivative and preparation salts thereof
WO2004067512A1 (fr) 2003-01-27 2004-08-12 Hanmi Pharm. Co., Ltd. Amlodipine camsylate stable et amorphe, procede de preparation associe et composition pour l'administration orale
NZ541454A (en) * 2003-01-31 2008-04-30 Daiichi Sankyo Co Ltd Medicine for prevention of and treatment for arteriosclerosis and hypertension
KR20040072363A (ko) * 2003-02-12 2004-08-18 주식회사 대웅 신규한 암로디핀 사이클라메이트 염 및 그의 제조방법
WO2004075825A2 (fr) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Formes posologiques d'amlodipine et leurs procedes de preparation
GB2415696B (en) * 2003-04-25 2007-06-20 Cipla Ltd Process for preparing amlodipine mesylate monohydrate
DE04770646T1 (de) 2003-04-25 2011-12-08 Cadila Healthcare Ltd. Salze von clopidogrel und herstellungsverfahren
JP2007516227A (ja) * 2003-05-16 2007-06-21 アンビット バイオサイエンシス コーポレーション ピロール化合物およびその使用
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
NZ543741A (en) 2003-05-30 2009-10-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
WO2005042485A1 (fr) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Sels d'addition acide d'amlodipine
KR100841409B1 (ko) 2003-12-16 2008-06-25 에스케이케미칼주식회사 암로디핀 겐티세이트 염과 이의 제조방법
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030602A1 (en) * 2004-03-16 2006-02-09 Sepracor Inc. (S)-amlodipine malate
EP1750862B1 (fr) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Composition pharmaceutique contenant de l'irbesartan
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006026555A2 (fr) * 2004-08-30 2006-03-09 Seo Hong Yoo Effet neuroprotecteur d'udca solubilise dans un modele ischemique focal
DE602005027727D1 (de) * 2004-10-15 2011-06-09 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
KR20070084455A (ko) * 2004-11-23 2007-08-24 워너-램버트 캄파니 엘엘씨 지질혈증 치료용 ｈｍｇ ｃｏ-ａ 환원효소 억제제로서의7-(2ｈ-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
WO2006059217A1 (fr) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Formes posologiques solides stables d'amlodipine bezylate, et procedes d'elaboration correspondants
US20080305158A1 (en) * 2004-12-28 2008-12-11 Ranbaxy Laboratories Limited Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine
WO2006085208A2 (fr) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Formes galeniques solides stables d'amlodipine et de benazepril
US20090298814A1 (en) * 2005-06-07 2009-12-03 Ramot At Tel Aviv Univeristy Ltd Novel salts of conjugated psychotropic drugs and processes of preparing same
TWI405580B (zh) * 2005-06-27 2013-08-21 Sankyo Co 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物
EP1930008A1 (fr) * 2005-09-28 2008-06-11 Teva Pharmaceutical Industries Ltd Composition stable d'hydrochlorure de benazepril
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
US8222296B2 (en) 2006-07-17 2012-07-17 Ramot At Tel-Aviv University Ltd. Conjugates comprising a GABA- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating CNS disorders
KR100795313B1 (ko) 2006-09-05 2008-01-21 현대약품 주식회사 암로디핀 베실레이트를 포함하는 약학 조성물
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor
CN101167724B (zh) * 2006-10-25 2012-08-22 北京华安佛医药研究中心有限公司 含有氨氯地平的药物组合物在制备治疗下尿路疾病药物中的用途
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
CA2673336A1 (fr) * 2006-12-21 2008-06-26 Xenoport, Inc. Promedicaments diesters dimethyle substitues a base de levodopa et procedes d'utilisation
US8058312B2 (en) * 2007-01-29 2011-11-15 Hanall Biopharma Co., Ltd. N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2009032286A2 (fr) 2007-09-06 2009-03-12 Nektar Therapeutics Al, Corporation Conjugués oligomère - bloqueur de canaux calciques
US8143314B1 (en) * 2007-09-13 2012-03-27 Robert Carl Stover Methods and formulations for treating ineffective or decreased esophageal motility
JP5292404B2 (ja) * 2007-09-21 2013-09-18 ハンオル バイオファーマ カンパニー，リミテッド Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物
MX2010007281A (es) 2007-12-31 2010-10-05 Lupin Ltd Composiciones farmaceuticas de amlodipina y valsartan.
WO2009101616A1 (fr) 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Nouveaux conjugués pour le traitement de maladies et troubles neurodégénératifs
CN101564536B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物缓控释制剂
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
MX2010014029A (es) 2008-06-27 2011-01-21 Avila Therapeutics Inc Compuestos de heteroarilo y usos de los mismos.
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
JP2012505885A (ja) * 2008-10-20 2012-03-08 ゼノポート，インコーポレーテッド レボドパエステルプロドラッグを合成する方法
US20110294860A1 (en) * 2008-12-17 2011-12-01 Medrx Co., Ltd. Aqueous oral preparation of stable amlodipine
BRPI0924136B8 (pt) 2009-01-23 2021-05-25 Hanmi Holdings Co Ltd composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
NZ601747A (en) * 2009-11-09 2014-08-29 Xenoport Inc Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
MX2012006566A (es) 2009-12-09 2012-11-29 Univ Ramot Metodo para mejorar las funciones cognoscitivas.
CN104876937B (zh) 2010-02-12 2017-07-28 辉瑞公司 8‑氟‑2‑{4‑[(甲氨基)甲基]苯基}‑1,3,4,5‑四氢‑6H‑氮杂*并[5,4,3‑cd]吲哚‑6‑酮的马来酸盐、其药物组合物及其用途
CA2789654A1 (fr) 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Formes cristallines du sel de trimesylate de perphenazine-gaba et procede de production associe
WO2011117876A1 (fr) 2010-03-26 2011-09-29 Fdc Limited Procédé amélioré pour la préparation de base libre d'amlodipine et des sels d'addition d'acide de celle-ci
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EP2425859A1 (fr) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulations de l'olmesartane
MX336875B (es) * 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
WO2012038963A1 (fr) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. Sel d'addition d'acide d'un conjugué nortriptyline-gaba et son procédé de préparation
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
SG10201508958WA (en) 2010-11-01 2015-11-27 Celgene Avilomics Res Inc Heterocyclic Compounds And Uses Thereof
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
WO2012071524A1 (fr) * 2010-11-24 2012-05-31 Ratiopharm Gmbh Sels d'arylsulfonates de fingolimod et leurs procédés de préparation
WO2013063401A1 (fr) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Méthodes de traitement d'une maladie ou d'une affection associée à la tyrosine-kinase btk (bruton's tyrosine kinase)
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
KR102090453B1 (ko) 2012-03-15 2020-03-19 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 염
WO2014100748A1 (fr) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Composés hétéroarylés et leurs utilisations
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
CA2900012A1 (fr) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Inhibiteurs d'erk et leurs utilisations
WO2014122585A1 (fr) 2013-02-08 2014-08-14 Wockhardt Limited Composition pharmaceutique stable d'amlodipine et de bénazépril ou de leurs sels
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016025561A1 (fr) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Formes et compositions d'un inhibiteur d'erk
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
CN104523588A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-硬脂酸离子液体及其制备方法和用途
CN104529877A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-癸酸离子液体及其制备方法和用途
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
EP3334466B1 (fr) 2015-08-14 2020-05-13 Endocyte, Inc. Méthode d'imagerie utilisant un composé chélateur
WO2017068532A1 (fr) 2015-10-23 2017-04-27 Ftf Pharma Private Limited Solution orale de dérivés de dihydropyridine
CN105395495A (zh) * 2015-11-30 2016-03-16 宜昌东阳光长江药业股份有限公司 一种含有苯磺酸氨氯地平的组合物及其制备方法
EP3219309A1 (fr) 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Compositions pharmaceutiques comprenant combinaisons à dose fixe de amlodipine, de candesartan cilexetil et de hydrochlorothiazide pour le traitement de l'hypertension
US20200316029A1 (en) 2016-05-30 2020-10-08 Boehringer Ingelheim International Gmbh Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
ES2886067T3 (es) 2016-10-07 2021-12-16 Silvergate Pharmaceuticals Inc Formulaciones de amlodipina
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP3501502A1 (fr) 2017-12-20 2019-06-26 Midas Pharma GmbH Compositions pharmaceutiques dosées fixes comprenant de l'amlodipine, du ramipril et de l'atorvastatine
CA3096101A1 (fr) 2018-04-11 2019-10-17 Silvergate Pharmaceuticals, Inc. Formulations d'amlodipine
CA3103616A1 (fr) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methodes de diminution de la tension arterielle avec une composition pharmaceutique de blocage de canal calcique de type dihydropyridine
JP7128969B2 (ja) 2019-01-18 2022-08-31 アストラゼネカ・アクチエボラーグ Ｐｃｓｋ９阻害剤及びその使用方法
US11253474B1 (en) 2021-02-01 2022-02-22 Liqmeds Worldwide Limited Pharmaceutical solution of amlodipine
EP4052695A1 (fr) 2021-03-05 2022-09-07 Midas Pharma GmbH Compositions pharmaceutiques orales stables à libération immédiate à dose fixe comprenant de l'amlodipine, de l'atorvastatine et du candésartan cilexétil
WO2023285646A1 (fr) 2021-07-15 2023-01-19 Adamed Pharma S.A Composition pharmaceutique comprenant de l'amlodipine, du candésartan cilexetil et de l'hydrochlorothiazide pour le traitement de l'hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816612A (en) * 1967-03-23 1974-06-11 Degussa Process for the production of basically reacting pharmaceuticals
US4032637A (en) * 1972-09-26 1977-06-28 Sandoz Ltd. Method of promoting sleep
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
JPS5547656A (en) * 1978-09-29 1980-04-04 Dainippon Pharmaceut Co Ltd 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative
CS228917B2 (en) * 1981-03-14 1984-05-14 Pfizer Method of preparing substituted derivatives of 1,4-dihydropyridine
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
ZA839187B (en) * 1982-12-10 1984-07-25 Ciba Geigy Ag Amide compounds

Also Published As

Publication number Publication date
CY1669A (en) 1993-05-14
EG18266A (en) 1992-12-30
KR870009998A (ko) 1987-11-30
KR950006710B1 (ko) 1995-06-21
FI85017B (fi) 1991-11-15
YU58087A (en) 1988-08-31
SE8701348D0 (sv) 1987-03-31
FI871470A (fi) 1987-10-05
AP50A (en) 1989-09-16
SK278435B6 (en) 1997-05-07
HU196962B (en) 1989-02-28
YU44801B (en) 1991-02-28
GB2188630A (en) 1987-10-07
NL8700791A (nl) 1987-11-02
SE8701348L (sv) 1987-10-05
FI85017C (fi) 1992-02-25
CS353991A3 (en) 1992-04-15
AU573123B2 (en) 1988-05-26
ATE49752T1 (de) 1990-02-15
DK170187D0 (da) 1987-04-03
PT84611B (pt) 1989-11-30
DD265142A5 (de) 1989-02-22
PL149532B1 (en) 1990-02-28
IT8719977A0 (it) 1987-04-03
FR2596758A1 (fr) 1987-10-09
IL82101A (en) 1991-01-31
FR2596758B1 (fr) 1988-12-02
GB2188630B (en) 1990-04-04
SU1498388A3 (ru) 1989-07-30
CN87102493A (zh) 1987-10-14
NO871408L (no) 1987-10-05
GR870525B (en) 1987-08-12
DK171708B1 (da) 1997-04-01
DK170187A (da) 1987-10-05
PT84611A (en) 1987-05-01
EP0244944B1 (fr) 1990-01-24
NO871408D0 (no) 1987-04-03
PL264982A1 (en) 1988-05-26
HUT43821A (en) 1987-12-28
CS236387A2 (en) 1989-01-12
CN1023800C (zh) 1994-02-16
US4879303A (en) 1989-11-07
GB8608335D0 (en) 1986-05-08
ECSP941129A (es) 1994-12-15
DE3761485D1 (de) 1990-03-01
JPS62240660A (ja) 1987-10-21
AP8700060A0 (en) 1987-02-01
UA6344A1 (uk) 1994-12-29
NZ219868A (en) 1989-02-24
IL82101A0 (en) 1987-10-30
CA1321393C (fr) 1993-08-17
CZ289095B6 (cs) 2001-10-17
GB8707653D0 (en) 1987-05-07
PH24348A (en) 1990-06-13
FI871470A0 (fi) 1987-04-03
BE1000130A4 (fr) 1988-04-12
ZA872439B (en) 1988-11-30
SG59692G (en) 1992-12-04
DE3710457A1 (de) 1987-10-08
SE463457B (sv) 1990-11-26
BG60698B2 (en) 1995-12-29
EP0244944A2 (fr) 1987-11-11
IE59457B1 (en) 1994-02-23
MY101177A (en) 1991-07-31
HK76092A (en) 1992-10-09
IN168414B (fr) 1991-03-30
AU7103087A (en) 1987-10-08
CS265237B2 (en) 1989-10-13
ES2002599A6 (es) 1988-08-16
AR242562A1 (es) 1993-04-30
EP0244944A3 (en) 1988-01-07
ES2012803B3 (es) 1990-04-16
MX5847A (es) 1993-08-01
IT1203853B (it) 1989-02-23
LU86812A1 (fr) 1987-08-12
NO172181C (no) 1993-06-16
GR3000394T3 (en) 1991-06-07
JPH037668B2 (fr) 1991-02-04
IE870869L (en) 1987-10-04
NO172181B (no) 1993-03-08

Similar Documents

Publication Publication Date Title
MA20938A1 (fr) Procede de preparation du besylate d'amlodipine.
PT85239A (en) Process for the preparation of-aryl-phenyl-ethyl-1h-1,2,4-triazole-1-propanenitriles
PT84237A (en) Process for preparing neurite-promoting factor
FR2621785B1 (fr) Procede de preparation d'un roux
EP0234776A3 (en) Process for 1,4-dihydropyridine compounds
FI873350A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,4-dihydropyridiinijohdannaisten valmistamiseksi
PT80956A (en) Process for preparing 1,4-dihydropyridines
YU201987A (en) Process for obtaining dihydropyridine
HUT45499A (en) Process for producing optically active 1,4-dihydropyridine derivatives
PT84959A (en) Process for the preparation of novel 1,4-dihydropyridines
FR2599369B1 (fr) Procede de preparation de disilylmethanes
MA21130A1 (fr) Procede de preparation de nouveaux aminopropionamides .
FR2609027B1 (fr) Procede de preparation de mercaptoalcools
FR2607808B1 (fr) Procede de preparation de trifluoromethylbenzonitrile a partir de trifluoromethylbenzaldehyde
FI891111A (fi) Menetelmä 1,4-dihydropyridiinijohdannaisten valmistamiseksi
FR2605318B1 (fr) Procede de preparation d'azetidinones.
PT85392A (en) Process for the preparation of 2,4-diamino-3-oxy-6-piperidylpurimidine
DE3760307D1 (en) Process for the preparation of 1,1,2-trialkoxyethane
GB2185035B (en) Process for preparing 1,4-diaminoanthraquinone-2,3-disubstituted compound
FR2602764B1 (fr) Composes dichlorotrifluoromethyltoluenes et procede de preparation de ces composes
FR2600333B1 (fr) Procede pour la preparation de 4-alcoxy-3-pyrroline-2-ones
DK0377437T3 (da) Fremgangsmåde til fremstilling af 2,4-diamino-6-piperidinylpyrimidin-3-N-oxid
PT85185A (en) Process for the preparation of 3,7-dihydro-3-n-propyl-1h-purine-2,6-dione
ZA875689B (en) Process for the preparation of 2,4-diamino-5-benzylpyrimidines
FR2600078B1 (fr) Procede de preparation de facteur xiii a partir du placenta